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Chronic spontaneous urticaria (CSU) is defined by 
the spontaneous appearance of wheals with or without 
oedema that persist for more than 6 weeks (1). The di-
sease affects up to 1% of the general population at some 
time in life (2) and can be very distressing, with severe 
reduction in quality of life (3). Little is known about the 
pathophysiology of CSU. 
First-line treatment for CSU is based on non-sedating, 
second-generation H1-antihistamine, given, if necessary, 
in 4-fold licensed doses (1). A significant proportion 
of patients with CSU remain poorly controlled on this 
treatment and alternative therapeutic approaches have to 
be considered. Several immune modulatory treatments 
have been used with varying effect; prednisolone, aza-
thioprine, mycophenolate mofetil, cyclosporine, sulfa-
salazine and methotrexate (4). 
Omalizumab, an anti-IgE monoclonal antibody 
(anti-IgE mAb), has been approved recently by the US 
Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) for the treatment of CSU, 
with promising results (5). 
Tumour necrosis factor alpha (TNF-α) is upregulated 
in both skin and serum in patients with urticaria (6, 7), 
and treatment with anti-TNF-α is hence expected to have 
an effect on chronic urticaria. There is limited data on 
the effect of anti-TNF-α treatment of urticaria. Wilson et 
al. (8) reported the effect in 6 patients with recalcitrant 
chronic urticaria treated with different TNF-α inhibitors, 
and Magerl et al. (9) describe remission of delayed pres-
sure urticaria in one patient treated with etanercept. 
The aim of this study was to investigate the effect of 
adalimumab on antihistamine refractory CSU.
MATERIALS AND METHODS
This proof-of-concept study was performed at the Department of 
Dermato-Allergology, Herlev and Gentofte Hospital in accordance 
with the Declaration of Helsinki. The study was approved by the 
local ethics committee (NO. H-3-2010-109) and The Danish Medi-
cines Agency (EUDRACT NO. 2010-022705-18). All subjects 
gave written, informed consent prior to enrolment.
Nine patients with CSU refractory to H1-antihistamine in 
4-fold licensed doses were included in the study. Baseline data 
for enrolled patients are shown in Table I. Prior to enrollment 
patients were screened for infectious diseases, including hepatitis, 
HIV and tuberculosis. The protocol for adalimumab treatment of 
psoriasis was followed.
The patients were treated subcutaneously with a loading dose 
of 80 mg adalimumab (Humira®; R&D systems, Abington, UK), 
followed by 40 mg every other week for 16 weeks. Patients were 
evaluated at baseline, during the treatment at week 4, 9 and 16, 
and after treatment discontinuation at week 18, 20 and 28. The 
patients were evaluated using a visual analogue score (VAS), the 
Urticaria Activity Score (UAS) (10), Dermatology Life Quality 
Index (DLQI), as well as questions from validated Danish versions 
of the Structured Itch Questionnaire, Becks Depression Inventory, 
Pittsburgh Sleep Quality Index, Brief Symptom Inventory and 
Somatosensory Amplification Scale. Patients reported symptoms 
for the previous week. The primary endpoint was change in UAS 
at week 16. TNF-α levels were measured at baseline and week 
9 using Quantikine HS enzyme-linked immunoassay (ELISA).
RESULTS
Nine patients completed the study. The results of UAS 
at baseline, week 4, 16, 20 and 28 are shown in Table I. 
Patients 2, 6 and 8 achieved complete remission, defined 
as a UAS of 0 at week 16. The effect lasted throughout 
the follow-up period. Patients 3, 4, 5 and 9 experienced 
improvement in symptoms, with a reduction in UAS, as 
well as DLQI and VAS scores at week 16. Two patients 
had no effect, measured with UAS, but did report im-
provement in DLQI and VAS at week 16. 
The mean ± SD level of serum TNF-α at baseline was 
1.19 ± 0.455 pg/ml and the mean reduction in TNF-α level 
week 9 was 10.8 ± 11.37% (not significant). 
No patients reported any adverse effect during the 
study and all screening blood tests during the study 
were normal. 
DISCUSSION
CSU is a disease with a significant reduction in quality 
of life that needs to be treated (3). There has been a 
strong demand for treatment options, which, with the 
introduction of omalizumab, has largely been met (5). 
There are, however, patients who do not respond to 
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Table I. Baseline data and results of Urticaria Activity 
Score, the past week, in 9 included patients
Pat. 
No.
Sex, 
age, 
years
Duration 
of CSU, 
years
Urticaria Activity Score
Remission
Week 
0
Week 
4
Week 
16
Week 
20
Week 
28
1 M/42 12 2 5 2 0 0 No
2 F/31 2 2 0 0 0 0 Complete
3 M/57 15 4 0 2 1 2 Partial
4 F/60 6 4 4 2 1 1 Partial
5 F/40 2 6 2 2 2 6 Partial
6 F/ 40 1 2 3 0 0 0 Complete
7a F/39 15 2 2 2 – – No
8 F/48 9 3 0 0 0 0 Complete
9 F/39 5 4 1 3 5 4 Partial
aLost to follow-up. CSU: chronic spontaneous urticaria.
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omalizumab or, due to side-effects, cannot be treated 
with this product. 
TNF-α is upregulated in both skin and serum of pa-
tients with urticaria, and TNF-α inhibitor is theoretically 
expected to have an effect on CSU, but this has only 
previously been investigated in two small studies (8, 9). 
In this small study we show an effect of TNF-α inhibi-
tors on CSU. The effect is not as good as that seen with 
omalizumab, and we do not suggest TNF-α-inhibitors as 
an alternative to omalizumab treatment; however, TNF-
α-inhibitors are worth considering as a treatment option 
for antihistamine refractory CSU in patients who do not 
respond to omalizumab or who, although rare, due to 
side-effects cannot be treated with this product. 
Interestingly, two-thirds of patients who experienced 
complete remission already had UAS 0 at week 4 and in 
these, as in all of the patients who experienced an effect, 
the effect lasted throughout the follow-up period, for 12 
weeks after medication was discontinued. This lasting 
effect was also seen in the 6 patients reported by Wilson 
et al. (8). The mechanism for this is unclear. Trials with 
omalizumab have demonstrated a mean of 10 weeks 
before symptoms return and re-administration is needed. 
The optimal duration of therapy and dosing interval for 
TNF-α-inhibitors have not been studied, but we suggest 
using the regimen known from psoriasis treatment, i.e. a 
80 mg subcutaneously loading dose followed by 40 mg 
subcutaneously every other week. 
In summary, this study shows an effect of adalimumab in 
patients with CSU, and thus should be considered for use 
in patients refractory to omalizumab. The study is limited 
by the small number of patients, but the results add to 
those of 2 other small studies published previously (8, 9).
Conflict of interest. Abbvie sponsored the medicine used in this 
study, but was not involved in the design of the study, interpreta-
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